Alivus Life Sciences [ALIVUS] vs Alembic [APLLTD] Detailed Stock Comparison

Alivus Life Sciences

NSE
Loading...

Alembic

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Alivus Life Sciences wins in 12 metrics, Alembic wins in 7 metrics, with 0 ties. Alivus Life Sciences appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricAlivus Life SciencesAlembicBetter
P/E Ratio (TTM)23.1031.67Alivus Life Sciences
Price-to-Book Ratio4.053.68Alembic
Debt-to-Equity Ratio2.0124.23Alivus Life Sciences
PEG Ratio2.592.14Alembic
EV/EBITDA15.8019.64Alivus Life Sciences
Profit Margin (TTM)20.65%8.84%Alivus Life Sciences
Operating Margin (TTM)25.80%12.13%Alivus Life Sciences
EBITDA Margin (TTM)25.80%12.13%Alivus Life Sciences
Return on Equity17.24%11.24%Alivus Life Sciences
Return on Assets (TTM)14.24%7.51%Alivus Life Sciences
Free Cash Flow (TTM)$2.25B$-4.76BAlivus Life Sciences
Dividend YieldN/A1.09%N/A
1-Year Return-12.68%-14.14%Alivus Life Sciences
Price-to-Sales Ratio (TTM)4.762.80Alembic
Enterprise Value$109.98B$202.41BAlembic
EV/Revenue Ratio4.582.97Alembic
Gross Profit Margin (TTM)55.07%76.18%Alembic
Revenue per Share (TTM)$196$347Alembic
Earnings per Share (Diluted)$40.29$30.66Alivus Life Sciences
Beta (Stock Volatility)0.110.47Alivus Life Sciences
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Alivus Life Sciences vs Alembic Stock Performance Analysis

Loading Price Chart...

Alivus Life Sciences
Alembic
Alivus Life Sciences Stock Overview | Alembic Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Alivus Life Sciences0.84%0.23%-0.97%-5.77%-11.16%-4.24%
Alembic-2.12%1.08%-1.48%-0.15%16.47%-8.74%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Alivus Life Sciences-12.68%-12.68%-12.68%-12.68%-12.68%-12.68%
Alembic-14.14%57.11%0.24%41.66%1,958.82%1,958.82%

News Based Sentiment: Alivus Life Sciences vs Alembic

Alivus Life Sciences

News based Sentiment: MIXED

September brought a mix of positive and neutral developments for Alivus Life Sciences. The credit rating upgrade and positive analyst outlook are encouraging, but the cautious investor reaction to quarterly results and shifts in shareholding patterns introduce some uncertainty. Overall, the month suggests a stable but evolving investment story.

View Alivus Life Sciences News Sentiment Analysis

Alembic

News based Sentiment: MIXED

September brought both positive and negative developments for Alembic Pharmaceuticals. The USFDA approval is a significant win, but the decline in net profit and bearish technical signals create uncertainty. The overall narrative is one of cautious optimism, requiring investors to closely monitor the company's performance in the coming quarters.

View Alembic News Sentiment Analysis

Performance & Financial Health Analysis: Alivus Life Sciences vs Alembic

MetricALIVUSAPLLTD
Market Information
Market Cap i₹114.96B₹191.31B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i59,802117,662
90 Day Avg. Volume i87,750100,824
Last Close₹946.85₹957.35
52 Week Range₹850.00 - ₹1,251.00₹725.20 - ₹1,303.90
% from 52W High-24.31%-26.58%
All-Time High₹1,251.00 (Feb 03, 2025)₹1,303.90 (Oct 07, 2024)
% from All-Time High-24.31%-26.58%
Growth Metrics
Quarterly Revenue Growth0.02%0.10%
Quarterly Earnings Growth0.09%0.15%
Financial Health
Profit Margin (TTM) i0.21%0.09%
Operating Margin (TTM) i0.26%0.12%
Return on Equity (TTM) i0.17%0.11%
Debt to Equity (MRQ) i2.0124.23
Cash & Liquidity
Book Value per Share (MRQ)₹229.77₹264.09
Cash per Share (MRQ)₹44.75₹4.25
Operating Cash Flow (TTM) i₹4.37B₹-3,101,700,000
Levered Free Cash Flow (TTM) i₹4.86B₹5.83B
Dividends
Last 12-Month Dividend Yield iN/A1.09%
Last 12-Month Dividend iN/A₹11.00

Valuation & Enterprise Metrics Analysis: Alivus Life Sciences vs Alembic

MetricALIVUSAPLLTD
Price Ratios
P/E Ratio (TTM) i23.1031.67
Forward P/E i18.7022.32
PEG Ratio i2.592.14
Price to Sales (TTM) i4.762.80
Price to Book (MRQ) i4.053.68
Market Capitalization
Market Capitalization i₹114.96B₹191.31B
Enterprise Value i₹109.98B₹202.41B
Enterprise Value Metrics
Enterprise to Revenue i4.582.97
Enterprise to EBITDA i15.8019.64
Risk & Other Metrics
Beta i0.110.47
Book Value per Share (MRQ) i₹229.77₹264.09

Financial Statements Comparison: Alivus Life Sciences vs Alembic

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)ALIVUSAPLLTD
Revenue/Sales i₹6.02B₹17.11B
Cost of Goods Sold i₹2.70B₹4.07B
Gross Profit i₹3.31B₹13.03B
Research & Development iN/AN/A
Operating Income (EBIT) i₹1.55B₹2.08B
EBITDA i₹1.81B₹2.87B
Pre-Tax Income i₹1.63B₹1.90B
Income Tax i₹414.46M₹364.80M
Net Income (Profit) i₹1.22B₹1.54B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)ALIVUSAPLLTD
Cash & Equivalents i₹710.62M₹834.80M
Total Current Assets i₹23.35B₹40.88B
Total Current Liabilities i₹4.70B₹24.12B
Long-Term Debt i₹509.58M₹467.70M
Total Shareholders Equity i₹28.17B₹51.90B
Retained Earnings iN/A₹43.94B
Property, Plant & Equipment i₹9.43B₹4.45B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)ALIVUSAPLLTD
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricALIVUSAPLLTD
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i59,802117,662
Average Daily Volume (90 Day) i87,750100,824
Shares Outstanding i122.54M196.56M
Float Shares i30.77M57.33M
% Held by Insiders i0.76%0.71%
% Held by Institutions i0.08%0.16%

Dividend Analysis & Yield Comparison: Alivus Life Sciences vs Alembic

MetricALIVUSAPLLTD
Last 12-Month Dividend iN/A₹11.00
Last 12-Month Dividend Yield iN/A1.09%
3-Year Avg Annual Dividend iN/A₹13.33
3-Year Avg Dividend Yield iN/A1.17%
3-Year Total Dividends iN/A₹40.00
Ex-Dividend DateN/AJul 29, 2025